Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcutis Biotherapeutics (ARQT) Liabilities and Shareholders Equity: 2020-2025

Historic Liabilities and Shareholders Equity for Arcutis Biotherapeutics (ARQT) over the last 6 years, with Sep 2025 value amounting to $371.0 million.

  • Arcutis Biotherapeutics' Liabilities and Shareholders Equity fell 15.18% to $371.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.4 billion, marking a year-over-year decrease of 16.78%. This contributed to the annual value of $348.9 million for FY2024, which is 2.20% up from last year.
  • Arcutis Biotherapeutics' Liabilities and Shareholders Equity amounted to $371.0 million in Q3 2025, which was up 5.26% from $352.4 million recorded in Q2 2025.
  • Arcutis Biotherapeutics' 5-year Liabilities and Shareholders Equity high stood at $508.9 million for Q3 2022, and its period low was $293.0 million during Q3 2023.
  • For the 3-year period, Arcutis Biotherapeutics' Liabilities and Shareholders Equity averaged around $373.8 million, with its median value being $352.4 million (2025).
  • Its Liabilities and Shareholders Equity has fluctuated over the past 5 years, first soared by 95.45% in 2021, then tumbled by 42.43% in 2023.
  • Quarterly analysis of 5 years shows Arcutis Biotherapeutics' Liabilities and Shareholders Equity stood at $408.2 million in 2021, then grew by 10.08% to $449.3 million in 2022, then declined by 24.02% to $341.4 million in 2023, then climbed by 2.20% to $348.9 million in 2024, then decreased by 15.18% to $371.0 million in 2025.
  • Its Liabilities and Shareholders Equity stands at $371.0 million for Q3 2025, versus $352.4 million for Q2 2025 and $344.1 million for Q1 2025.